This was interesting. Have a read of this news piece below then...

This was interesting. Have a read of this news piece below then follow link to Selecta Biosciences' website where biodegradable nanoparticles are highlighted. Looking forward to learning more about what was featured in latest presentation.

Selecta and Sanofi join forces

http://www.pmlive.com/intelligence/sales/2012/december/pharma_deals_during_november_2012

Top of the leaderboard this month is the exclusive, global collaboration between Selecta Biosciences and Sanofi based on Selecta’s synthetic vaccine particle (SVP) platform.

Specifically, the collaboration is to develop and commercialise a tolerogenic, antigen-specific immunotherapy against an undisclosed, life-threatening food allergen and an option to develop two additional immunotherapeutic candidates for food or airborne allergens. The SVP technology uniquely engineers biodegradable nanoparticles to create synthetic vaccines with fully integrated components, including antigens and adjuvants. It is claimed to specifically target immune cells and to facilitate an optimal immune response.

Selecta is eligible to receive several pre-clinical, clinical, regulatory and sales milestones totalling $300m for each immunotherapy, plus up to double-digit tiered royalties for each commercialised immunotherapy.

Here's the link to Selecta's site...

Biocompatible composition. Selecta's tSVP vaccines are composed of synthetic, biocompatible, biodegradable polymeric materials with established clinical safety profiles from decades of clinical use.

tSVP™ - A new class of synthetic vaccines for Optimal Immune Response